全文获取类型
收费全文 | 1162篇 |
免费 | 145篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 96篇 |
妇产科学 | 19篇 |
基础医学 | 121篇 |
口腔科学 | 44篇 |
临床医学 | 106篇 |
内科学 | 334篇 |
皮肤病学 | 29篇 |
神经病学 | 21篇 |
特种医学 | 189篇 |
外科学 | 64篇 |
综合类 | 98篇 |
预防医学 | 73篇 |
眼科学 | 9篇 |
药学 | 71篇 |
中国医学 | 3篇 |
肿瘤学 | 71篇 |
出版年
2024年 | 3篇 |
2023年 | 16篇 |
2022年 | 15篇 |
2021年 | 24篇 |
2020年 | 21篇 |
2019年 | 10篇 |
2018年 | 20篇 |
2017年 | 42篇 |
2016年 | 38篇 |
2015年 | 30篇 |
2014年 | 63篇 |
2013年 | 72篇 |
2012年 | 28篇 |
2011年 | 27篇 |
2010年 | 65篇 |
2009年 | 69篇 |
2008年 | 30篇 |
2007年 | 67篇 |
2006年 | 40篇 |
2005年 | 25篇 |
2004年 | 22篇 |
2003年 | 11篇 |
2002年 | 10篇 |
2001年 | 31篇 |
2000年 | 13篇 |
1999年 | 18篇 |
1998年 | 77篇 |
1997年 | 65篇 |
1996年 | 59篇 |
1995年 | 51篇 |
1994年 | 45篇 |
1993年 | 42篇 |
1992年 | 11篇 |
1991年 | 6篇 |
1990年 | 18篇 |
1989年 | 21篇 |
1988年 | 24篇 |
1987年 | 13篇 |
1986年 | 19篇 |
1985年 | 17篇 |
1984年 | 9篇 |
1983年 | 12篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 12篇 |
1975年 | 9篇 |
排序方式: 共有1357条查询结果,搜索用时 0 毫秒
41.
Procedural variation in the performance of primary percutaneous coronary intervention for ST‐elevation myocardial infarction: A SCAI‐based survey study of US interventional cardiologists 下载免费PDF全文
Austin Chiang MD Hemal Gada MD MBA Susheel K. Kodali MD Michael S. Lee MD Allen Jeremias MD Duane S. Pinto MD MPH Sripal Bangalore MD MHA Robert W. Yeh MD MSc Timothy D. Henry MD Georgina Lopez‐Cruz BS MSHA Roxana Mehran MD Ajay J. Kirtane MD SM 《Catheterization and cardiovascular interventions》2014,83(5):721-726
42.
Lin Zhang Joseph JY Sung Jun Yu Siew C Ng Sunny H Wong Chi H Cho Simon SM Ng Francis KL Chan William KK Wu 《The Journal of pathology》2014,233(2):103-112
Helicobacter pylori and Epstein–Barr virus (EBV) account for roughly 80% and 10%, respectively, of gastric carcinomas worldwide. Autophagy is an evolutionarily conserved and intricately regulated cellular process that involves the sequestration of cytoplasmic proteins and organelles into double‐membrane autophagosomes that eventually fuse with lysosomes for degradation of the engulfed content. Emerging evidence indicates that xenophagy, a form of selective autophagy, plays a crucial role in the pathogenesis of H. pylori‐ and EBV‐induced gastric cancer. Xenophagy specifically recognizes intracellular H. pylori and EBV and physically targets these pathogens to the autophagosomal–lysosomal pathway for degradation. In this connection, H. pylori or EBV‐induced dysregulation of autophagy may be causally linked to gastric tumourigenesis and therefore can be exploited as therapeutic targets. This review will discuss how H. pylori and EBV infection activate autophagy and how these pathogens evade recognition and degradation by the autophagic pathway. Elucidating the molecular aspects of H. pylori‐ and EBV‐induced autophagy will help us better understand the pathogenesis of gastric cancer and promote the development of autophagy modulators as antimicrobial agents. Published by John Wiley & Sons, Ltd 相似文献
43.
44.
45.
46.
Marwan SM Al-Nimer 《World journal of diabetes》2022,13(5):417-419
Hyperandrogenism and hyperinsulinemia have resulted from dysfunction of the theca cell of the ovary and adipose tissue and each one potentiates the other in patients with androgen excess disorders e.g., polycystic ovary disease and idiopathic hirsutism. Possible external and/or internal triggers can produce such cellular dysfunction. There is evidence that sodium valproate acts as a trigger of cellular dysfunction and produces both hyperinsulinemia and hyperandrogenism. Therefore, the elimination of these triggers can help the patients to recover from hyperinsulinemia, insulin resistance and hyperandrogenism. 相似文献
47.
48.
Ilias Nikolakopoulos MD James W. Choi MD Khaldoon Alaswad MD Jaikirshan J. Khatri MD Oleg Krestyaninov MD Dmitrii Khelimskii MD Robert W. Yeh MD PhD Farouc A. Jaffer MD PhD Catalin Toma MD Mitul Patel MD Ehtisham Mahmud MD Nicholas J. Lembo MD Manish Parikh MD Ajay J. Kirtane MD SM Ziad A. Ali MD Fotis Gkargkoulas MD Barry Uretsky MD Abdul M. Sheikh MD Evangelia Vemmou MD Iosif Xenogiannis MD Bavana V. Rangan BDS MPH Santiago Garcia MD Shuaib Abdullah MD Subhash Banerjee MD M. Nicholas Burke MD Emmanouil S. Brilakis MD PhD Dimitri Karmpaliotis MD PhD 《Catheterization and cardiovascular interventions》2021,97(4):658-667
49.
50.
Weisdorf DJ; Verfaillie CM; Davies SM; Filipovich AH; Wagner JE Jr; Miller JS; Burroughs J; Ramsay NK; Kersey JH; McGlave PB 《Blood》1995,85(12):3452-3456
Delay in hematologic recovery after bone marrow transplantation (BMT) can extend and amplify the risks of infection and hemorrhage, compromise patients' survival, and increase the duration and cost of hospitalization. Because current studies suggest that granulocyte- macrophage (GM) colony-stimulating factor (CSF) may potentiate the sensitivity of hematopoietic progenitor cells to G-CSF, we performed a prospective, randomized trial comparing GM-CSF (250 micrograms/m2/d x 14 days) versus sequential GM-CSF x 7 days followed by G-CSF (5 micrograms/kg/d x 7 days) as treatment for primary or secondary graft failure after BMT. Eligibility criteria included failure to achieve a white blood cell (WBC) count > or = 100/microL by day +21 or > or = 300/microL by day +28, no absolute neutrophil count (ANC) > or = 200/microL by day +28, or secondary sustained neutropenia after initial engraftment. Forty-seven patients were enrolled: 23 received GM-CSF (10 unrelated, 8 related allogeneic, and 5 autologous), and 24 received GM- CSF followed by G-CSF (12 unrelated, 7 related allogeneic, and 5 autologous). For patients receiving GM-CSF alone, neutrophil recovery (ANC > or = 500/microL) occurred between 2 and 61 days (median, 8 days) after therapy, while those receiving GM-CSF+G-CSF recovered at a similar rate of 1 to 36 days (median, 6 days; P = .39). Recovery to red blood cell (RBC) transfusion independence was slow, occurring 6 to 250 days (median, 35 days) after enrollment with no significant difference between the two treatment groups (GM-CSF: median, 30 days; GM-CSF+G- CSF; median, 42 days; P = .24). Similarly, platelet transfusion independence was delayed until 4 to 249 days (median, 32 days) after enrollment, with no difference between the two treatment groups (GM- CSF: median, 28 days; GM-CSF+G-CSF: median, 42 days; P = .38). Recovery times were not different between patients with unrelated donors and those with related donors or autologous transplant recipients. Survival at 100 days after enrollment was superior after treatment with GM-CSF alone. Only 1 of 23 patients treated with GM-CSF died versus 7 of 24 treated with GM-CSF+G-CSF who died 16 to 84 days (median, 38 days) after enrollment, yielding Kaplan-Meier 100-day survival estimates of 96% +/- 8% for GM-CSF versus 71% +/- 18% for GM-CSF+G-CSF (P = .026). These data suggest that sequential growth factor therapy with GM-CSF followed by G-CSF offers no advantage over GM-CSF alone in accelerating trilineage hematopoiesis or preventing lethal complications in patients with poor graft function after BMT.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献